Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miguel Gil

Showing results (131-140 of 217) with videos related to

Pageof 22
Sort By:
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 16, 2023
Ten-year experience of bone SBRT in breast cancer: analysis of predictive factors of effectivenessHéctor Pérez-Montero, Alicia Lozano, Rodolfo de Blas, et al.
The Breast Journal|February 14, 2020
Predictive factors for omitting lymphadenectomy in patients with node-positive breast cancer treated with neo-adjuvant systemic therapySergi Fernandez-Gonzalez, Catalina Falo, Maria J Pla, et al.
Scientific Reports|October 9, 2024
Neoadjuvant sunitinib plus exemestane in post-menopausal women with hormone receptor-positive/HER2-negative early-stage breast cancer (SUT_EXE-08): a phase I/II trialBartomeu Fullana, Serafín Morales, Anna Petit, et al.
Frontiers in Oncology|August 27, 2019
PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single InstitutionSonia Pernas, Anna Petit, Fina Climent, et al.
Frontiers in Oncology|October 11, 2019
Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single InstitutionSonia Pernas, Anna Petit, Fina Climent, et al.
The American Journal of Pathology|June 29, 2011
Expression of endoplasmic reticulum stress proteins is a candidate marker of brain metastasis in both ErbB-2+ and ErbB-2- primary breast tumorsRebeca Sanz-Pamplona, Ramón Aragüés, Keltouma Driouch, et al.
Biomedicines|April 30, 2021
Ectopic FOXP3 Expression in Combination with TGF-β1 and IL-2 Stimulation Generates Limited Suppressive Function in Human Primary Activated Thymocytes Ex VivoJorge Gallego-Valle, Sergio Gil-Manso, Ana Pita, et al.
Cancers|May 28, 2022
Safety and Efficacy of Crizotinib in Combination with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Glioblastoma: Phase Ib GEINO 1402 TrialMaría Martínez-García, Guillermo Velasco, Estela Pineda, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 23, 2024
Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohortHelena Pla, Eudald Felip, Verónica Obadia, et al.
International Journal of Surgery (London, England)|February 4, 2017
Feasibility, accuracy and prognosis of sentinel lymph node biopsy before neoadjuvant therapy in breast cancer. A prospective studyAmparo Garcia-Tejedor, Catalina Falo, Cecilia Quetglas, et al.
Pageof 22

Showing results (131-140 of 217) with videos related to

Sort By:
Pageof 22
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 16, 2023
Ten-year experience of bone SBRT in breast cancer: analysis of predictive factors of effectivenessHéctor Pérez-Montero, Alicia Lozano, Rodolfo de Blas, et al.
The Breast Journal|February 14, 2020
Predictive factors for omitting lymphadenectomy in patients with node-positive breast cancer treated with neo-adjuvant systemic therapySergi Fernandez-Gonzalez, Catalina Falo, Maria J Pla, et al.
Scientific Reports|October 9, 2024
Neoadjuvant sunitinib plus exemestane in post-menopausal women with hormone receptor-positive/HER2-negative early-stage breast cancer (SUT_EXE-08): a phase I/II trialBartomeu Fullana, Serafín Morales, Anna Petit, et al.
Frontiers in Oncology|August 27, 2019
PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single InstitutionSonia Pernas, Anna Petit, Fina Climent, et al.
Frontiers in Oncology|October 11, 2019
Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single InstitutionSonia Pernas, Anna Petit, Fina Climent, et al.
The American Journal of Pathology|June 29, 2011
Expression of endoplasmic reticulum stress proteins is a candidate marker of brain metastasis in both ErbB-2+ and ErbB-2- primary breast tumorsRebeca Sanz-Pamplona, Ramón Aragüés, Keltouma Driouch, et al.
Biomedicines|April 30, 2021
Ectopic FOXP3 Expression in Combination with TGF-β1 and IL-2 Stimulation Generates Limited Suppressive Function in Human Primary Activated Thymocytes Ex VivoJorge Gallego-Valle, Sergio Gil-Manso, Ana Pita, et al.
Cancers|May 28, 2022
Safety and Efficacy of Crizotinib in Combination with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Glioblastoma: Phase Ib GEINO 1402 TrialMaría Martínez-García, Guillermo Velasco, Estela Pineda, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 23, 2024
Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohortHelena Pla, Eudald Felip, Verónica Obadia, et al.
International Journal of Surgery (London, England)|February 4, 2017
Feasibility, accuracy and prognosis of sentinel lymph node biopsy before neoadjuvant therapy in breast cancer. A prospective studyAmparo Garcia-Tejedor, Catalina Falo, Cecilia Quetglas, et al.
Pageof 22